kabutan

ONO PHARMA, Apr-Dec (Cumulative 3Q) Net Income Increases by 22%, Exceeds Full-Year Plan

Mon Feb 2, 2026 12:00 pm JST Earnings

4528 ONO PHARMACEUTICAL CO., LTD. 【IFRS】

Earnings Report

ONO PHARMACEUTICAL CO., LTD. <4528> [TSE Prime] announced its financial results (based on IFRS) at noon (12:00) on February 2nd. The consolidated net income for the cumulative third quarter of the fiscal year ending March 2026 (April to December) increased 21.8% from the same period last year, reaching 68.9 billion yen. Progress toward the full-year plan of 67.0 billion yen is 102.9%, already exceeding the target and also exceeding the five-year average of 90.5%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net loss for the January to March period (4Q) is expected to further decrease loss of 1.94 billion yen (compared to a loss of 6.54 billion yen in the same period last year). However, if the fourth-quarter performance remains at the same level as the first three quarters, the full-year plan may be increased.

In the most recent three-month period, from October to December (3Q), the consolidated net income increased 50.6% from the same period last year, reaching 28.8 billion yen. The operating profit margin jumped from 16.4% in the same period last year to 25.9%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 389,903 144,626 147,292 110,544 229.1 90.0 Jan 31, 2024 IFRS
Apr - Dec, 2024 374,562 70,754 72,037 56,592 120.5 121.4 Feb 3, 2025 IFRS
Apr - Dec, 2025 397,036 88,292 89,377 68,949 146.8 105.1 Feb 2, 2026 IFRS
YoY +6.0% +24.8% +24.1% +21.8% +21.8%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 246,532 10,959 11,784 12,612 26.9 40 May 8, 2025 IFRS
Oct - Mar, 2025 Guidance 232,864 32,931 32,825 26,911 57.3 40 Oct 30, 2025 IFRS
YoY -5.5% +200.5% +178.6% +113.4% +113.3%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 502,672 159,935 163,734 127,977 266.6 80 May 9, 2024 IFRS
Mar, 2025 486,871 59,747 59,328 50,047 106.6 80 May 8, 2025 IFRS
Mar, 2026 Guidance 490,000 85,000 85,000 67,000 142.6 80 May 8, 2025 IFRS
YoY +0.6% +42.3% +43.3% +33.9% +33.8%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 134,223 21,966 24,493 19,157 40.8 16.4 Feb 3, 2025 IFRS
Jan - Mar, 2025 112,309 -11,007 -12,709 -6,545 -13.9 -9.8 May 8, 2025 IFRS
Apr - Jun, 2025 127,536 21,995 22,650 17,673 37.6 17.2 Aug 1, 2025 IFRS
Jul - Sep, 2025 129,600 30,074 29,525 22,416 47.7 23.2 Oct 30, 2025 IFRS
Oct - Dec, 2025 139,900 36,223 37,202 28,860 61.4 25.9 Feb 2, 2026 IFRS
YoY +4.2% +64.9% +51.9% +50.6% +50.6%

Related Articles